Biography/Memoir

Lykos… moved to patent MDMA in late 2022, filing reveals

…another big ‘if’ is whether the company will even obtain FDA approval for its MDMA-assisted therapy at all…

Specifically, Lykos’ patent application claims a composition comprising a salt or solvate of MDMA along with one or more excipients, where the average particle size in the composition is, at its broadest, between 50 and 400 microns, and, at its narrowest, between 100 and 200 microns.

Original Article (Psychedelic Alpha):
Lykos Therapeutics moved to patent MDMA in late 2022, filing reveals
Artwork Fair Use: Microtechua

Biography/Memoir

Patented…

Biography/Memoir

…launch of…